Precigen (PGEN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.05
- EPS estimate
- −$0.01
- EPS surprise
- +513.22%
- Revenue surprise
- +96.47%
- Revenue
- $55.0M
- Revenue estimate
- $28.0M
- Reported
- Aug 4, 2026
Precigen reported Q2 2026 results on August 4, 2026. It posted a profit of $0.05 per share against an expected loss of $0.01, the first profitable quarter in the table. Revenue was $55.0 million, 96.47% above the $28.0 million estimate. A year earlier, Q2 2025 brought a loss of $0.09 per share on revenue of $878,000, so revenue was about 63 times higher.
Every other quarter in the table was a loss. Annual losses per share widened from $0.38 in 2022 to $0.39 in 2023, $0.49 in 2024 and $1.40 in 2025. Q3 2025 alone lost $1.06 per share, against an expected $0.09 loss. Revenue stayed under $3 million a quarter from Q4 2022 to Q3 2025, then rose to $4.6 million in Q4 2025, $23.3 million in Q1 2026 and $55.0 million in Q2 2026. Precigen beat the EPS estimate in seven of the last 20 quarters, including the last three.
Third-quarter results came out between November 8 and November 14 in each of the past five years. That points to early or mid November 2026 for the Q3 report. It will show whether revenue holds near recent levels and whether the quarter is again profitable.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | −$0.01 | $0.05 | +513.22% | $55.0M | SEC |
| Q1 2026 | May 13, 2026 | −$0.03 | −$0.02 | +40.48% | $23.3M | SEC |
| Q4 2025 | Mar 25, 2026 | −$0.08 | −$0.07 | +16.67% | $4.6M | SEC |
| Q3 2025 | Nov 13, 2025 | −$0.09 | −$1.06 | −1028.86% | $2.9M | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.09 | −$0.09 | −3.81% | $878,000.00 | SEC |
| Q1 2025 | May 14, 2025 | −$0.13 | −$0.18 | −38.46% | $1.3M | SEC |
| Q4 2024 | Mar 19, 2025 | −$0.05 | −$0.07 | −40.38% | $1.2M | SEC |
| Q3 2024 | Nov 14, 2024 | −$0.09 | −$0.09 | −4.29% | $953,000.00 | SEC |
| Q2 2024 | Aug 14, 2024 | −$0.10 | −$0.23 | −140.33% | $717,000.00 | SEC |
| Q1 2024 | May 14, 2024 | −$0.09 | −$0.10 | −13.64% | $1.1M | SEC |
| Q4 2023 | Mar 19, 2024 | −$0.08 | −$0.13 | −64.56% | $1.2M | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.08 | −$0.08 | +0.00% | $1.4M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.10 | −$0.08 | +20.40% | $1.8M | SEC |
| Q1 2023 | May 10, 2023 | −$0.09 | −$0.10 | −8.11% | $1.9M | SEC |
| Q4 2022 | Mar 6, 2023 | −$0.10 | −$0.11 | −10.00% | $1.8M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.14 | −$0.04 | +70.37% | $16.7M | — |
| Q2 2022 | Aug 8, 2022 | −$0.15 | −$0.13 | +10.34% | $2.9M | — |
| Q1 2022 | May 9, 2022 | −$0.11 | −$0.10 | +4.76% | $32.0M | — |
| Q4 2021 | Mar 1, 2022 | −$0.12 | −$0.13 | −8.33% | $24.2M | — |
| Q3 2021 | Nov 8, 2021 | −$0.15 | −$0.15 | −2.25% | $21.6M | — |
Quarterly revenue
Frequently asked questions
When did Precigen (PGEN) last report earnings?
Precigen last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did PGEN beat earnings estimates?
Yes. Precigen reported EPS of $0.05 for Q2 2026 against a −$0.01 estimate — a 513.22% beat.
How much revenue did PGEN report last quarter?
Precigen reported $55.0M in revenue for Q2 2026, against a consensus estimate of $28.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.